Aquilon and partners cross the mid-term milestone for Aeronext

Aquilon Pharma, together with its partners, recently reached an important milestone (the “go/no go milestone” on the research part) for the Biowin Aeronext Project (Convention 8183).

Following presentation to the Aeronext scientific committee, the consortium has now received mid-term approval from the Walloon Region’s to continue and finalise this important project (4.863.844 € total amount).

The panel of international experts sitting on the jury notes that “the project remains very interesting and has strong industrial potential”.

Share this article

Share this article on your networks to share it with your friends

More Corporate activities, Highlight news